BioSpace News Archive

Technavio analysts forecast the global veterinary lasers market to grow at a CAGR of over 12% during the forecast period, according to their latest market research report. This

Patient safety is a top priority at Rush Foundation Hospital, which was the first hospital in East Mississippi and West Alabama to deploy Xenex LightStrike™ Germ-Zapping Robots™ to enhance environmental cleanliness by disinfecting and destroying hard-to-kill germs, bacteria and superbugs in hard-to-clean places.

After school sports are a large part of many adolescent lives. These sports provide healthy competition that shapes young athletes where they may develop self-discipline and teamwork, and improve physical fitness and coordination.

Managed Health Care Associates, Inc. (MHA) and SoftWriters, operating as part of MHA since 2015, continue aligning efforts to deliver excellent value and enable the success of our Members and Customers

Recipient of Fourth Annual Ferolyn Powell Leadership Award to be Presented

The MemorialCare Heart & Vascular Institute at Long Beach Medical Center has received the Get With The Guidelines® -- Heart Failure Gold Plus Quality Achievement Award for implementing specific quality improvement measures outlined by the American Heart Association/American College of Cardiology Foundation’s secondary prevention guidelines for patients with heart failure.

Paradigm Spine, LLC, a leader in providing solutions for the treatment of lumbar spinal stenosis, announces issuance of a BlueCross BlueShield of South Carolina Medical Policy, entitled “Interspinous and Interlaminar Stabilization/Distraction Devices (Spacers)” dated August 2018. T

Dr. Chris Yu, Chief Executive Officer of international life sciences corporation, Anpac Bio-Medical Science Company (Anpac Bio), announced today the organization has surpassed two significant, biotechnology industry milestones: earning 101 patents issued; and filing over 200 patents in 20 countries worldwide.

he Government of Canada is taking major steps to improve health outcomes and access to health services for First Nations through health transformation investments in First Nation communities across Canada.

Phase I/II Trial to Investigate Combination Therapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma to take place at Dana-Farber Cancer Institute